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Open accObjectives: Lung deflation and inflation during cardiac surgery with cardiopulmonary bypass contributes to
pulmonary dysfunction postoperatively. Theophylline treatment for lung diseases has traditionally been thought
to act by phosphodiesterase inhibition; however, increasing evidence has suggested other plausible mechanisms.
We investigated the effects of deflation and reinflation on signaling pathways (p38-mitogen-activated protein
kinase [MAPK], extracellular signal-regulated kinase 1 and 2 [ERK1/2], and Akt) and whether theophylline
influences the deflation-induced lung injury and associated signaling.
Methods: Isolated rat lungswereperfused (15mL/min)withdeoxygenated ratblood inbicarbonate buffer andventi-
lated. After 20minutes’ equilibration, the lungswere deflated (60minutes, aerobic perfusion 1.5mL/min), followed
by reinflation (60 minutes, anaerobic reperfusion 15 mL/min). Compliance, vascular resistance, and kinase phos-
phorylationwereassessedduringdeflation and reinflation.Theeffects ofSB203580 (50mM), ap38-MAPKinhibitor,
and theophylline (0.083 mM [therapeutic] or 3 mM [supratherapeutic]) on physiology and signaling were studied.
Results: Deflation reduced compliance by 44% compared with continuously ventilated lungs. p38-MAPK and
Akt phosphorylation increased (three to fivefold) during deflation and reinflation, and ERK1/2 phosphorylation
increased (approximately twofold) during reinflation. SB203580 had no effect on lung physiology or ERK1/2
and Akt activation. Both theophylline doses increased cyclic adenosine monophosphate, but only 3 mM
theophylline improved compliance. p38-MAPK phosphorylation was not affected by theophylline; 0.083 mM
theophylline inhibited reinflation-induced ERK1/2 phosphorylation (72%  3%); and 3 mM theophylline
inhibited Akt phosphorylation during deflation (75%  5%) and reinflation (87%  4%).
Conclusions: Lung deflation and reinflation stimulates differential p38-MAPK, ERK1/2, and Akt activation,
suggesting a role in lung injury during cardiopulmonary bypass. However, p38-MAPK was not involved in
the compromised compliance. A supratherapeutic theophylline dose protected lungs against deflation-
induced injury and was associated with inhibition of phosphoinositide 3-kinase/Akt rather than phosphodies-
terase. (J Thorac Cardiovasc Surg 2014;148:2335-44)E
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SPulmonary dysfunction after cardiac surgery with
cardiopulmonary bypass (CPB) affects a significant number
of patients, with clinical manifestations ranging from
fever and unproductive cough to acute respiratory distress
syndrome.1 During CPB, the lungs are deflated and
excluded from the pulmonary circulation, with the blood
supply provided only through the bronchial arteries
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ess under CC BY-NC-ND license.reduced blood flow and the systemic inflammatory response
to the extracorporeal circuit, leads to pulmonary injury.2
Although strategies to reduce post-CPB lung injury have
been examined,3 few have been applied in clinical practice,
and the ideal management for the lungs during CPB remains
controversial.
Our previous experimental studies of the long-term
preservation of the rat lung have shown that theophylline
(clinically, aminophylline) improved lung function after
prolonged hypothermic storage.4 Theophylline is an inex-
pensive, orally administered drug that has historically
been used for asthma and chronic obstructive pulmonary
disease; however, it has a narrow therapeutic window
(recommended dose, 5-15 mg/mL), and its mechanism of
action remains uncertain.5 Traditionally, its clinical effects
have been attributed to nonselective phosphodiesterase
(PDE) inhibition and cyclic adenosine monophosphate
(cAMP) elevation.6 However, evidence has been
increasing for other plausible mechanisms, including
adenosine receptor antagonism,7 interleukin-10 release,8
inhibition of phosphoinositide 3-kinase (PI3K) activity,9diovascular Surgery c Volume 148, Number 5 2335
Abbreviations and Acronyms
BB ¼ bicarbonate buffer
cAMP ¼ cyclic adenosine monophosphate
CPB ¼ cardiopulmonary bypass
ERK1/2 ¼ extracellular signal-regulated kinase
1 and 2
MAPK ¼ mitogen-activated protein kinase
PDE ¼ phosphodiesterase
PI3K ¼ phosphoinositide 3-kinase
SBB ¼ sanguineous BB
TBST ¼ Tris-buffered saline with Tween 20
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Sand activation of histone deacetylases.10 Intraoperative
administration of theophylline attenuated the post-CPB
systemic inflammatory response in patients undergoing
valve replacement.11 However, that small study was
limited by the use of aprotinin, which might interact
with theophylline.11 Thus, the effect of theophylline on
CPB-induced lung injury requires further investigation.
Little is known about the cell types and signaling
cascades activated in lungs during CPB. Studies in animal
models of CPB have reported activation of pulmonary
extracellular signal-regulated kinase 1 and 2 (ERK1/2)12
and p38-mitogen-activated protein kinase (MAPK),12,13
localized in pulmonary epithelial cells, bronchial smooth
muscle, and vascular endothelial cells.12 Their histologic
localization suggests they could be involved in vascular
permeability,14 neutrophil adhesion,15 and cytokine produc-
tion.16 Accumulating evidence has indicated that the PI3K/
Akt pathway is involved invariousmodels of lung injury.17,18
PI3K is a family of lipid-modifying enzymes involved in cell
survival, proliferation, secretion, and glucose transport.19
However, the downstream targets of the PI3K pathway and
its role in CPB-induced lung injury remain unknown.
The etiology of post-CPB pulmonary dysfunction is
multifactorial. Although the contribution of each factor
and the underlying molecular mechanisms remain
unknown, pulmonary abnormalities result, at least in part,
by atelectasis.20 Thus, we hypothesized that deflation and
reinflation, such as occurs during CPB, will stimulate the
MAPK/PI3K pathways and promote lung injury that can
be ameliorated by theophylline. To test this hypothesis,
we used isolated perfused rat lungs to model the clinical
scenario of CPB and established the kinetic effects of
deflation and reinflation on the MAPK/PI3K pathways.
We also determined the influence of MAPK and PDE
inhibition on physiology and signaling.METHODS
Lung Preparation
All rats received humane care in compliance with the ‘‘Guidance
on the Operation of the Animals (Scientific Procedures) Act 1986’’2336 The Journal of Thoracic and Cardiovascular Sur(Her Majesty’s Stationary Office, London, UK). Lungs from male Wistar
rats (weight, 250-330 g) were isolated and perfused as described previ-
ously.4 In brief, the rats were anesthetized with pentobarbitone, at a dose
(160 mg/kg intraperitoneally) that induced a surgical level of general anes-
thesia, established by the absence of corneal reflexes. The rats were then
ventilated by positive pressure (80 breaths/min, room air, Harvard Small
Animal Ventilator; Harvard Apparatus, Harvard Bioscience, Holliston,
Mass), heparinized (500 IU into the inferior vena cava), and exsanguinated.
After the thorax was opened, the pulmonary artery and left atrium were
cannulated, and the lungs were removed and suspended in a sealed cham-
ber. Perfusion was begun with modified bicarbonate buffer (BB, composi-
tion, NaCl 118.5 mmol/L, KCl 3.8 mmol/L, KH2PO4 1.2 mmol/L,
NaHCO3 25.0 mmol/L, CaCl2 2.0 mmol/L, MgSO4 1.2 mmol/L, glucose
10.0 mmol/L) mixed with whole rat blood (4:1) to produce sanguineous
BB (SBB, approximately 6% hematocrit and 23 g/L hemoglobin). The
apparatus included the lung chamber, a perfusate reservoir, and a mem-
brane deoxygenator (gassed with 100% nitrogen); all components were
water-jacketed (37C) and connected with noncoated silicone tubing.
The SBB was gassed with 100% carbon dioxide intermittently to maintain
a pH at 7.35 to 7.45. Perfusionwas nonpulsatile, at a flow rate of 15mL/min
and pressure of approximately 14 cmH2O. Perfusate was passed through
the deoxygenator before entering the lung; buffer leaving the lungs was
returned to the reservoir and recycled. Thus, oxygenation of the perfusate
was by the isolated lungs. The peak tracheal pressure applied by the venti-
lator was set to give a tidal volume of 2.0 to 2.3 mL (0.7 mL/100 g animal
weight), and a positive end-expiratory pressure of 1 to 2 cmH2O was
applied. Every 10 minutes, a deep breath (sigh) was initiated to avoid
atelectasis. Pressure transducers were connected to the tracheal, arterial,
and venous cannulas. The peak tracheal pressure and tidal volume, calcu-
lated by integration of the flow through a pneumotachograph connecting
the trachea to the ventilator, were measured. The ratio of the tidal volume
to tracheal pressure was taken as a measure of dynamic lung compliance.
The difference in pressures between the pulmonary artery and venous
cannulas divided by the perfusate flow rate measured the vascular resis-
tance. All outputs from the pressure transducers and pneumotachograph
were recorded using PowerLab analogue–digital converter and PowerLab
Chart software (ADInstruments Ltd, Oxford, UK). The parameters were
sampled at 30 points in each breath and dynamic compliance and vascular
resistance calculated during a 10-breath period for each point examined.
Experimental Protocol
The lungswere perfused at 15mL/min (deoxygenated SBB) for an initial
20-minute period to establish control lung function. During clinical CPB,
bronchial artery lung perfusion, with a flow of 10% that of the normal
pulmonary artery flow rate,2 is maintained. To mimic this clinical scenario,
ventilation was stopped, and the lungs were allowed to deflate while
perfusion continued with oxygenated SBB (gassed with 95% oxygen/5%
carbon dioxide) at a rate of 1.5 mL/min. After deflation, the lungs were
reperfused with deoxygenated SBB at 15 mL/min (for the period indicated)
and ventilated. Each experimental group consisted of the lungs from 6 rats.
The physiologic parameters were measured during equilibration and
reinflation for the deflated lungs and throughout the experiment for the
control lungs. After each experimental period, the lungs were washed
with BB for 2 minutes, frozen in liquid nitrogen, and stored at 80C.
Study 1
The effect of deflation on lung physiology was studied in lungs deflated
for 60 minutes and reinflated for 60 minutes (Figure 1, A). This duration of
deflation and reinflation had been established in preliminary studies (data
not shown) as sufficient to induce significant lung injury (compliance at
60 minutes of reinflation, 60%  4%, 49%  8%, 47%  3%, 32% 
5% of baseline after 15, 30, 60, and 90 minutes of deflation, respectively)
and also to observe any acute effects on recovery. In time-matched controls,
the lungs were continuously ventilated and perfused (15 mL/min,gery c November 2014
FIGURE 1. A, Experimental protocols. The lungs were either ventilated and perfused for 140 minutes (control) or subjected to 20 minutes of equilibration,
followed by deflation (60 minutes) and reinflation (60 minutes) in the absence (D/R) or presence of inhibitors (D/Rþinhibitor). The samples were collected
at the points indicated. B, Effects of lung deflation and reinflation on dynamic compliance and vascular resistance. Dynamic compliance and vascular resis-
tance of the control lungs or lungs subjected to deflation and reinflation (D/R) were measured. Data are expressed as themean standard error of themean of
6 lungs per group. *P<.05 compared with ventilated lungs (area under the curve, unpaired t test). Bas, Baseline.
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kinase activation during deflation was assessed in lungs deflated for 5,
10, 15, 30, or 60 minutes. The course of kinase activation during reinflation
was studied in lungs deflated for 60 minutes and reinflated for 5, 10, 15, 30,
or 60 minutes (Figure 1, A).
Study 2
We have previously shown that a high (supratherapeutic) dose of
theophylline (3 mM) protects lungs against injury during prolonged
hypothermic storage.4 Therefore, we tested this theophylline dose against
deflation-induced lung injury and compared it with a dose within the
therapeutic range (0.083mM, corresponding to 15 mg/mL).21 TheophyllineThe Journal of Thoracic and Car(0.083 or 3 mM, dissolved in BB) or the p38-MAPK inhibitor SB203580
(50 mM) was added to the perfusate from the start of the experiment, and
the lungs were subjected to deflation for 60 minutes, followed by
reperfusion and reinflation for 60 minutes. Kinase activation was assessed
in lung samples at the end of equilibration (baseline), deflation, and
reinflation (Figure 1 A).
Immunoblotting
The lung tissue was homogenized with 5 mL/g of buffer (20 mM
b-glycerophosphate, pH 7.5, 20 mM sodium fluoride, 2 mM ethylenedia-
minetetraacetic acid, 0.2 mM Na3VO4, 10 mM benzamidine, 5 mM
dithiothreitol, and 1% [vol/vol] TritonX100) containing complete proteasediovascular Surgery c Volume 148, Number 5 2337
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samples were centrifuged (4C, 10 minutes, 10,000g), and the protein
concentration was determined in the supernatant using the Bradford
method. The samples were boiled with 0.33 volume of sodium dodecyl
sulfate-polyacrylamide gel electrophoresis sample buffer (10% [wt/vol]
sodium dodecyl sulfate, 13% [vol/vol] glycerol, 300 mM Tris-HCl, pH
6.8, 130 mM dithiothreitol, and 0.2% [wt/vol] bromophenol blue). The
proteins were separated using sodium dodecyl sulfate-polyacrylamide gel
electrophoresis on 10% acrylamide, 0.275% [wt/vol] bis-acrylamide
slab gels and transferred electrophoretically onto a polyvinyldine diflouride
membrane. Nonspecific binding sites were blocked (20 minutes) with 5%
(wt/vol) nonfat milk powder in Tris-buffered saline with Tween 20
(TBST) buffer (20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 0.1% [vol/vol]
Tween 20). The membranes were incubated overnight with primary
antibodies in TBST buffer containing 1% (wt/vol) bovine serum
albumin and then washed in TBST buffer (3 3 5 minutes). Primary
antibodies (Cell Signaling Technology, Inc, Beverly, Mass) against
phospho(Thr180/Tyr182)-p38-MAPK, phospho(Thr202/Tyr204)-ERK1/
2, phospho(Thr308)-Akt, phospho(Ser82)-hsp27, total p38-MAPK, and
total ERK1/2 were diluted 1/1000. The membranes were incubated
for 60 minutes with horseradish peroxidase-conjugated secondary
antibodies (Santa Cruz Biotechnology Inc., Dallas, Tex), diluted 1/5000
in TBST buffer containing 1% (wt/vol) nonfat milk powder, and washed
in TBST buffer (33 5 minutes). The bands were detected using enhanced
chemiluminescence, and the blots were quantified using scanning
densitometry.
Determination of Lung cAMP
cAMP was measured in lung tissue powders using a commercially
available immunoassay kit (Sigma-Aldrich, Inc, St Louis, Mo) according
to the manufacturer’s instructions.
Statistical Analysis
Data are presented as the mean  standard error of the mean. The
number of independent experiments has been indicated in the relevant
sections. To compare the effects of the various treatments on lung function
during the course of reperfusion, trapezoid integration was used to
calculate the area under the curve for each parameter for each rat. These
individual values were then used for statistical comparisons of the various
groups. Statistical analyses (1-way analysis of variance with post hoc
Dunnett’s t test for multiple comparisons or 2-tailed Student’s t test, as
appropriate) were performed using GraphPad Prism (GraphPad Software,
San Diego, Calif).RESULTS
Study 1
Deflation-induced lung injury. We studied the effect of
deflation in isolated perfused rat lungs mimicking clinical
CPB. If unchallenged, the preparations were stable for 4
hours. Stability of the control perfusions of 140 minutes’
duration was achieved for compliance and vascular
resistance (Figure 1, B). Lung deflation with aerobic
perfusion for 60 minutes reduced compliance by 44.5%
compared with ventilated controls (Figure 1, B, area under
the curve analysis, 85-140 minutes). In contrast, vascular
resistance was not affected by deflation (Figure 1, B).
Differential phosphorylation of p38-MAPK, Akt, and
ERK1/2 by deflation and reinflation. The time course
of activation of signaling pathways in lungs during
CPB has not been fully elucidated. Thus, the kinetics of2338 The Journal of Thoracic and Cardiovascular Surp38-MAPK, Akt, and ERK1/2 phosphorylation in deflated
and reinflated isolated lungs was examined. p38-MAPK
phosphorylation increased throughout deflation, and the
maximal levels (5.5-fold compared with baseline) were
attained after 60 minutes (Figure 2). The p38-MAPK
phosphorylation levels declined during early reinflation
but peaked again (4-fold compared with baseline) after
60 minutes. Akt was also phosphorylated during deflation,
but only moderately (approximately twofold compared
with baseline), and this was delayed (60 minutes;
Figure 2). On reinflation, Akt phosphorylation increased
further (3-fold compared with baseline, 30 minutes)
and remained elevated. In contrast, the ERK1/2 basal
levels of phosphorylation were decreased during deflation
(0.5-fold compared with baseline) and were only weakly
increased at the end of reinflation (Figure 2). Equal
protein loading was verified by immunoblotting for total
p38-MAPK. Thus, lung deflation and reinflation, such as
would occur during cardiac surgery with CPB, promotes
activation of p38-MAPK, Akt, and ERK1/2 with different
time courses.
Study 2
Effect of SB203580 on lung physiology and signaling.
Because p38-MAPK was potently activated during
deflation and reinflation, we examined its role in
deflation-induced lung injury using the p38-MAPK
catalytic site inhibitor SB203580. No significant difference
was seen in compliance or vascular resistance after
deflation in the presence of SB203580 compared with the
control deflated lungs (Figure 3, A). p38-MAPK, ERK1/2,
and Akt phosphorylation by deflation and reinflation was
not reduced by SB203580. To confirm inhibition of
p38-MAPK activity by SB203580 in our system, we
examined the phosphorylation of hsp27(Ser82), a down-
stream target of p38-MAPK. SB203580 significantly
reduced hsp27 phosphorylation by deflation and reinflation
(Figure 3, B).
Effect of theophylline on deflation-induced lung injury
and signaling. Compliance was markedly improved after
deflation in the presence of 3 mM theophylline. In contrast,
the therapeutic dose of theophylline (0.083 mM) had no
effect (Figure 4). Theophylline at both concentrations
appeared to reduce vascular resistance during lung
reinflation, but this effect was not significant (Figure 4).
Theophylline is generally accepted as a nonspecific PDE
inhibitor21; therefore, we assessed its effect on the
intracellular cAMP levels. Lungs treated with isoprenaline
(105 M) were used as positive controls.22 Deflation and
reinflation decreased the lung cAMP content (57  6.9
and 42.2  2.3 pmol/mL, respectively, compared with
baseline, 67.6  6.0 pmol/mL), but the difference failed
to reach statistical significance (Figure 5, A). Theophylline
at 0.083 and 3 mM reversed the decrease in cAMP contentgery c November 2014
FIGURE 2. Lung deflation and reinflation promoted differential phosphorylation of p38-mitogen-activated protein kinase (MAPK), extracellular signal-
regulated kinase 1 and 2 (ERK1/2), andAkt. The lungswere subjected to 20minutes of equilibration (baseline, 0minutes), followed by deflation (60minutes)
and reinflation and reperfusion (60 minutes). The tissue samples were collected at the points indicated. Whole cell extracts were immunoblotted for phos-
phorylated (p)-p38-MAPK, p-ERK, or p-Akt. Equal protein loading was verified by immunoblotting for total p38-MAPK. The blots were quantified using
scanning densitometry. The results were normalized to the baseline measurements and are expressed as the mean standard error of the mean of 4 lungs per
group. *P<.05 compared with baseline (1-way analysis of variance with Dunnett’s test). Bas, Baseline.
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FIGURE 3. Effect of p38-mitogen-activated protein kinase (MAPK) inhibition on lung physiology and signaling. The lungs were subjected to deflation and
reinflation in the absence of SB203580 (D/R) or in the presence of 50 mM of SB203580 (D/RþSB203580). A, Dynamic compliance and vascular resistance
were measured throughout the experiment. Data are expressed as the mean  standard error of the mean of 6 lungs per group. B, Tissue samples were
collected at the end of equilibration (baseline), deflation, or reperfusion. Whole cell extracts were immunoblotted for phosphorylated (p)-p38-MAPK,
p-hsp27, p-ERK, or p-Akt. Equal protein loading was verified by immunoblotting for total p38-MAPK or total ERK1/2. The blots were quantified using
scanning densitometry. The results were normalized to total p38-MAPK or total ERK1/2 and are expressed as the mean  standard error of the mean of
4 lungs per group. NP< .05 compared with deflation without SB203580; *P< .05 compared with reinflation without SB203580 (unpaired t test).
ERK1/2, Extracellular signal-regulated kinase 1 and 2; Bas, baseline.
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and 115.8  14.9 pmol/mL, respectively (Figure 5, A).
Similarly, theophylline increased cAMP during reinflation
to 59.5  0.9 pmol/mL (0.083 mM) and 94.0  8.8
pmol/mL (3 mM).
p38-MAPK phosphorylation by deflation and reinflation
was not affected by theophylline (Figure 5, B and C). The
reinflation-induced phosphorylation of ERK1/2 was only
inhibited by 0.083 mM theophylline (by 72.33%  3.6%
compared with control reinflated lungs). In contrast,
3 mM theophylline markedly reduced Akt phosphorylation
during deflation (by 75.6%  5.4%) and reinflation
(by 87.3%  4.4%); however, the lower dose had no
effect (Figure 5, B and C). These results suggest that
the 2 doses of theophylline have different effects on2340 The Journal of Thoracic and Cardiovascular Surdeflation-induced lung injury and the underlying signaling
pathways.
DISCUSSION
The present study is, to our knowledge, the first to
demonstrate the lung injury promoted by deflation and
reinflation, together with the activation of MAPK/Akt
signaling pathways in isolated perfused rat lungs. Although
similar observations have been previously shown in pig and
rat CPB models,12,13 our ex vivo model of CPB has the
advantage of separation from confounding whole body
complications and overcomes sampling limitations. Thus,
we established a detailed time course of p38-MAPK,
ERK1/2, and Akt activation under conditions mimicking
deflation and reinflation during cardiac surgery with CPB.gery c November 2014
FIGURE 4. A high dose of theophylline improved lung function after
deflation. After equilibration, the lungs were subjected to deflation/reinfla-
tion in the absence of theophylline (D/R) or in the presence of theophylline
(D/Rþtheophylline 0.083 or 3 mM). Dynamic compliance and vascular
resistance were measured throughout the experiment. Data are expressed
as the mean  standard error of the mean of 6 lungs per group. *P<.05
compared with no treatment (area under the curve analysis and 1-way anal-
ysis of variance with Dunnett’s test).
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the deflation and reinflation-induced lung injury, and we
have provided evidence for its potential mechanism of
action.
Most cardiac surgery units maintain deflation during
CPB to ensure exposure and stability of the surgical
field. Nonetheless, pulmonary complications post-
operatively result, at least in part, from lung collapse
rather than increased edema.20 In agreement with this,
deflation markedly reduced compliance in our isolated
perfused lungs but had no effect on vascular resistance.
Other studies of isolated lungs4,23 have also reported
compromised breathing mechanics (ie, tidal volume,
compliance), with vascular resistance remainingThe Journal of Thoracic and Carunaffected, suggesting that compliance is a sensitive
indicator of lung physiology.23
The pulmonary signaling pathways activated during
cardiac surgery with CPB remain uncertain. In a pig CPB
model, pulmonary p38-MAPK activation was seen during
CPB and reperfusion12; however, the time course of this
activation was limited. In our isolated rat lungs, we also
observed p38-MAPK activation, with a biphasic pattern
during deflation and reinflation. The role of p38-MAPK in
deflation-induced injury was studied using SB203580,
which inhibits p38-MAPK activity by occupying the
adenosine triphosphate–binding pocket within the kinase
cleft.24 Thus, SB203580 inhibited phosphorylation of
hsp27 downstream of p38-MAPK but had no effect on
p38-MAPK phosphorylation itself. Phosphorylation of
Akt or ERK1/2 by deflation and reinflation was not affected
by SB203580, confirming the specificity of the inhibitor for
p38-MAPK. In a rat CPB model, SB203580 reduced
pulmonary tissue levels of tumor necrosis factor-a and
interleukin-1b, decreased lung water content and
inflammatory cell infiltration, and improved lung histologic
changes.13 However, it did not improve lung compliance
after deflation. Thus, the p38-MAPK signaling pathway
seems to be involved in the CPB-induced proinflammatory
response rather than the compromised breathing mechanics.
Oscillations in ERK1/2 activation during institution and
weaning of CPB have been illustrated in myocardial
tissue25,26 and skeletal muscle and mesenteric vessels in
pigs.25 These systemic changes in ERK1/2 activity have
been attributed to shear stress.25 In the same model, CPB
produced a sustained activation of pulmonary ERK1/2
that continued during post-CPB reperfusion.12 In contrast,
deflation in the isolated rat lungs induced dephosphoryla-
tion of ERK1/2, but the total protein levels of the kinases
were unchanged. The discrepancy between our results and
those from the previous study might reflect differences in
anesthetic, surgical, and/or perfusion techniques resulting
from the different CPB models. ERK1/2 phosphorylation
increased as soon as ventilation and perfusion was restored.
Hence, the alterations in ERK1/2 activity might be
associated with the mechanical forces of ventilation or the
changes in perfusion. Dephosphorylation of ERK1/2 was
also reported after CPB in myocardial tissue and was
accompanied by upregulation of the MAPK phosphatase-
1.25,26 However, MAPK phosphatase-1 is not solely
responsible for ERK1/2 dephosphorylation after CPB.
MAPK/ERK kinase 1/2, the kinase that phosphorylates
ERK1/2, was also decreased in the activated form after
CPB. The course of ERK1/2 phosphorylation in our model
suggested the involvement of upstream inhibitory signals
such as MAPK/ERK kinase 1/2, rather than upregulation
of inhibitory molecules such as MAPK phosphatase-1.
The role of the ERK1/2 pathway in lung injury is
controversial. Thus, pharmacologic inhibition of ERK1/2diovascular Surgery c Volume 148, Number 5 2341
FIGURE 5. Effect of theophylline on lung cyclic adenosinemonophosphate (cAMP) content and signaling. A, The lungs were either perfusedwith isopren-
aline (105 M, positive controls) or were deflated and reinflated in the absence of theophylline (D/R) or in the presence of theophylline (D/Rþtheophylline
0.083 or 3 mM). The tissue samples were collected at the end of equilibration (baseline [Bas]), deflation, or reinflation, and the cAMP levels were deter-
mined. Data are expressed as the mean standard error of the mean of 4 lungs per group.NP<.05 compared with deflation without theophylline; *P<.05
compared with reinflation without theophylline (1-way analysis of variance with Dunnett’s test). B and C, Cell extracts were immunoblotted for phosphor-
ylated (p)-p38-MAPK, p-ERK, p-Akt, total p38-MAPK, or total ERK1/2. The results were normalized to total p38-MAPK or total ERK1/2 and were ex-
pressed as the mean  standard error of the mean of 3 lungs per group.NP<.05 compared with deflation without theophylline; *P<.05 compared with
reinflation without theophylline (unpaired t test). ERK1/2, Extracellular signal-regulated kinase 1 and 2; MAPK, mitogen-activated protein kinase.
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injury and cytokine release,27 although the same inhibitor
had no effect on ventilation-induced cytokine release.28 In
our model, reinflation-induced ERK1/2 phosphorylation
was inhibited by the therapeutic dose of theophylline;
however, this was not associated with improved lung
compliance after deflation. Additional studies are required
to clarify the regulation of ERK1/2 activation by deflation
and reinflation and its role in the development of
CPB-induced lung injury.
The PI3K pathway has been shown to be involved in lung
injury in various models.17,18,29 Local delivery of PI3K
inhibitors prevented endotoxin- and elastase-induced
lung injury through direct inhibitory effects on airway
epithelial cells, neutrophils, and macrophages.29 Further-
more, inactivation of phosphatase and tension homolog,
the phosphatase that negatively regulates the PI3K/Akt2342 The Journal of Thoracic and Cardiovascular Surpathway, resulted in exacerbated acute lung injury.30 The
present study is, to our knowledge, the first to demonstrate
that Akt, a physiologic readout of PI3K activation, is
phosphorylated in lungs by deflation and reinflation during
CPB. The downstream targets of the PI3K/Akt pathway in
CPB-induced lung injury are unknown. In patients with
acute respiratory distress syndrome, overventilation
increased proinflammatory cytokine release by PI3K/Akt-
mediated activation of the transcription factor nuclear
factor-kappaB.17,28 Moreover, silencing of the PI3Kg
gene attenuated ventilator-induced lung injury indepen-
dently of cytokine release; the proposed mechanism
involves enhancement of pulmonary apoptosis,31 poten-
tially through activation of the proapoptotic protein Bax.32
The severity of post-CPB lung injury could be reduced
pharmacologically without compromising the exposure of
the surgical field. Our previous studies of experimentalgery c November 2014
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supratherapeutic concentration of theophylline (3 mM)
improved compliance and gas exchange after prolonged
hypothermic storage.4 In agreement with these results,
theophylline increased compliance after deflation at this
high concentration (3 mM) but not at a lower dose within
the therapeutic range (0.083 mM). This protective effect
might have resulted from theophylline’s bronchodilator
action, which is minimized at therapeutic concentrations.5
PDE inhibition has been proposed as the major
molecular mechanism of bronchodilatation.6 In our
previous comparative studies, theophylline was more
effective in improving lung function after prolonged
hypothermic storage than other specific PDE isoenzyme
inhibitors.4 Nevertheless, both high and low doses of
theophylline increased cAMP levels in isolated perfused
lungs; however, only the high dose improved compliance
after deflation. Thus, the protective effect of theophylline
against deflation-induced injury is likely to be independent
of its PDE inhibitory properties. Theophylline in high
doses could also act by adenosine receptor antagonism,7 a
mechanism likely to account for its cardiac side effects,
such as arrhythmias.21 However, a comparison of the effects
of theophylline, xanthine amine congener (adenosine A1
receptor antagonist), and enprofylline (selective PDE
inhibitor) on lung function after storage suggested that
adenosine antagonism was not involved in theophylline’s
mechanism of action.33 The improvement in lung function
by theophylline was associated with inhibition of the
deflation- and reinflation-induced Akt phosphorylation.
Although often overlooked, theophylline has been
identified as a direct inhibitor of PI3K lipid and serine
kinase activity in vitro.9 Thus, theophylline treatment of
hamster ovary cells or rat soleus muscle blocked
insulin-stimulated Akt phosphorylation, with a half
maximal inhibitory concentration in the vicinity of 1
mM.9 In agreement with this, theophylline inhibited Akt
phosphorylation by deflation and reinflation in isolated
lungs at 3 mM. Furthermore, a low concentration of
theophylline, used as an add-on therapy, restored
corticosteroid sensitivity in patients with chronic obstruc-
tive pulmonary disease by inhibition of oxidant-activated
PI3Kd.34 The major side effects of theophylline result
from PDE inhibition35; hence, its PI3K inhibitory
properties provide a novel approach for the development
of therapeutic strategies against CPB-induced lung injury.
Theophylline’s mechanism of action in the pathophysio-
logic conditions of CPB requires further investigation.
Study Limitations
The main limitation of our model was that the lungs were
only perfused by the pulmonary artery and not also by the
bronchial arteries, such as occurs in patients undergoing
CPB. We attempted to compensate for this by perfusingThe Journal of Thoracic and Carthe lungs at 10% of the normal flow (1.5 mL/min) to
mimic the bronchial artery perfusion with oxygenated
perfusate. We also acknowledge that hypothermia,
routinely applied during CPB, was not included in our
model. Additionally, the degree of hemodilution of our
perfusate was greater than would be used in patients
receiving CBP; however, it eliminated the need for blood
donor animals. These differences to the clinical situation
could have influenced the clinical relevance of our findings.
It would be important in the future to examine these strate-
gies in a more relevant CPB model in either rats or pigs.CONCLUSIONS
Deflation and reinflation, such as occurs during
cardiac surgery with CPB, activates the p38-MAPK,
Akt, and ERK1/2 signaling pathways and induces
lung injury. Understanding CPB pathophysiology is
critical to improving patient outcomes, and information
on potential interventions should also be applicable to
emerging extracorporeal membrane oxygenation technolo-
gies. Theophylline protects against CPB-induced lung
injury but at a high dose that is not clinically suitable, and
this effect was associated with Akt inhibition. Studies using
alternative theophylline-like drugs with a wider therapeutic
range are required.References
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